Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Effect of catechol- O

Effect of catechol- O Original article 239 Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study Inna E. Tchivileva, Pei Feng Lim, Shad B. Smith, Gary D. Slade, Luda Diatchenko, Samuel A. McLean and William Maixner Introduction Three common haplotypes in the gene significantly reduced a composite pain index (P = 0.02) encoding catechol-O-methyltransferase (COMT) have but did not decrease other clinical and experimental been associated with pain modulation and the risk of pain ratings. When stratified by the COMT high activity developing chronic musculoskeletal pain, namely haplotype, a beneficial effect of propranolol on pain temporomandibular disorder (TMD). Haplotypes coding perception was noted in patients not carrying this for higher enzymatic activity were correlated with lower haplotype, a diminished benefit was observed in the pain perception. Rodent studies showed that COMT heterozygotes, and no benefit was noted in the inhibition increases pain sensitivity through b -adrenergic homozygotes. 2/3 receptors. We hypothesized that the nonselective Conclusion COMT haplotypes may serve as genetic b-adrenergic antagonist propranolol will reduce clinical predictors of propranolol treatment outcome, identifying and experimental pain in TMD patients in a manner a subgroup of TMD patients who will benefit from dependent http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Pharmacogenetics & Genomics Wolters Kluwer Health

Effect of catechol- O

Maixner, William
Pharmacogenetics & Genomics , Volume 20 (4) – Apr 1, 2010
Download PDF
10 pages

Loading next page...
 
/lp/wolters-kluwer-health/effect-of-catechol-o-ozFExYX25p

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
1744-6872
eISSN
1744-6880
DOI
10.1097/FPC.0b013e328337f9ab
pmid
20216107
Publisher site
See Article on Publisher Site

Abstract

Original article 239 Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study Inna E. Tchivileva, Pei Feng Lim, Shad B. Smith, Gary D. Slade, Luda Diatchenko, Samuel A. McLean and William Maixner Introduction Three common haplotypes in the gene significantly reduced a composite pain index (P = 0.02) encoding catechol-O-methyltransferase (COMT) have but did not decrease other clinical and experimental been associated with pain modulation and the risk of pain ratings. When stratified by the COMT high activity developing chronic musculoskeletal pain, namely haplotype, a beneficial effect of propranolol on pain temporomandibular disorder (TMD). Haplotypes coding perception was noted in patients not carrying this for higher enzymatic activity were correlated with lower haplotype, a diminished benefit was observed in the pain perception. Rodent studies showed that COMT heterozygotes, and no benefit was noted in the inhibition increases pain sensitivity through b -adrenergic homozygotes. 2/3 receptors. We hypothesized that the nonselective Conclusion COMT haplotypes may serve as genetic b-adrenergic antagonist propranolol will reduce clinical predictors of propranolol treatment outcome, identifying and experimental pain in TMD patients in a manner a subgroup of TMD patients who will benefit from dependent

Journal

Pharmacogenetics & Genomics – Wolters Kluwer Health

Published: Apr 1, 2010

There are no references for this article.